PGBD4 Activators
PGBD4 Activators are a collection of compounds that enhance the functional activity of PGBD4 by modulating various cellular signaling pathways in which this protein may be involved. Forskolin and Zaprinast, for example, increase intracellular cAMP levels, indirectly leading to the activation of protein kinase A (PKA) and other cAMP-dependent pathways that may phosphorylate substrates or proteins that influence PGBD4's activity. Similarly, 8-Bromo-cAMP and Dibutyryl-cAMP (dbcAMP) serve as cAMP analogs that resist degradation, thereby sustaining the activation of these pathways and potentially enhancing the phosphorylation and activation of PGBD4. Another class of activators includes Phorbol 12-myristate 13-acetate (PMA), which activates protein kinase C (PKC). This activation can trigger a cascade of phosphorylation events that may modify PGBD4's interaction with other proteins or its localization within the cell, leading to its functional enhancement. Epigallocatechin gallate (EGCG), by inhibiting competitive protein kinases, can shift the signaling equilibrium to favor PGBD4 activation, suggesting a role for PGBD4 in pathways affected by EGCG's inhibition.
To further elucidate the biochemical landscape of PGBD4 activators, calcium signaling emerges as a critical regulatory mechanism. Both Ionomycin and A23187 are calcium ionophores that elevate intracellular calcium levels, which can activate calcium-dependent signaling pathways and, subsequently, kinases or phosphatases that interact with PGBD4, enhancing its activity. Similarly, Thapsigargin, by inhibiting the SERCA pump, leads to increased calcium levels and might indirectly potentiate PGBD4 activity via calcium-dependent signaling cascades. Sphingosine-1-phosphate (S1P) enriches the activator spectrum by engaging G-protein-coupled receptors and initiating a cascade of signaling events that could enhance PGBD4's role in the cell. Inhibitors of specific kinases and phosphatidylinositol 3-kinase (PI3K), such as LY294002, along with MEK inhibitors like U0126, could recalibrate intracellular signaling networks, reducing competitive signaling and potentially augmenting pathways where PGBD4 is a critical effector, thereby indirectly enhancing its activity. Collectively, these PGBD4 activators influence a constellation of interlinked pathways, each converging to potentiate PGBD4 through fine-tuned biochemical modulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, increasing cAMP levels. Elevated cAMP activates PKA, which may enhance phosphorylation events and subsequent activation of PGBD4 in signaling pathways. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a PKC activator. Activation of PKC can lead to phosphorylation cascades that could enhance the activity of PGBD4 by altering its interaction with other proteins or its subcellular localization. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is known to inhibit certain protein kinases, potentially reducing competitive signaling and enhancing pathways where PGBD4 is involved by changing the phosphorylation dynamics of the protein or associated substrates. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium concentration, potentially activating calcium-dependent signaling pathways and kinases that could lead to the activation of PGBD4. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P is involved in the sphingolipid signaling pathway. It can activate G-protein-coupled receptors, potentially leading to downstream signaling events that enhance the activity of PGBD4 through protein-protein interactions. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, possibly shifting the balance of signaling pathways towards those where PGBD4 is functional, thus enhancing its activity by altering the phosphorylation status of PGBD4 or related proteins. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor, which could lead to the activation of PGBD4 by reducing competitive signaling through the MAPK pathway and potentially enhancing signaling pathways in which PGBD4 is involved. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is a calcium ionophore, like ionomycin, and could similarly enhance PGBD4 activity through calcium-dependent signaling pathways that are influenced by changes in intracellular calcium levels. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
8-Bromo-cAMP is a cAMP analog that resists degradation, leading to sustained activation of PKA and other cAMP-dependent pathways, which may indirectly enhance PGBD4 activity through phosphorylation events. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits phosphodiesterases, leading to increased cAMP levels, similarly to forskolin, and potentially enhancing PGBD4 activity through cAMP-dependent signaling pathways. | ||||||